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I. Urinary excretion of tryptophan metabolites of the kynurenine pathway before and after a loading dose of 2 g of L-tryptophan (both before and during supplementation with vitamin B 6 ) was studied in normal young male subjects and in elderly male subjects with prostatic diseases.
2. The increase in urinary excretion of tryptophan metabolites in the normal male subjects after a loading dose of 2 g of L-tryptophan was unchanged after vitamin B 6 supplementation, indicating that this dose does not exceed the normal capacity of the kynurenine pathway.
3. It is therefore concluded that a loading dose of 2 g of L-tryptophan is preferable when studying the capacity of the kynurenine pathway.
4. In about three-quarters of the elderly male subjects with prostatic diseases, the capacity of the kynurenine pathway was normal.
5. In about one-quarter of the subjects with prostatic diseases after a loading dose of 2 g of L-tryptophan there was abnormally high urinary excretion of one or several tryptophan metabolites, which could be normalized by vitamin B 6 , indicating that the capacity of the kynurenine pathway had been exceeded in these subjects.
6. Urinary excretion of individual tryptophan metabolites after a loading dose of 2 g of L-tryptophan was constant in the same subject when studied under unchanged conditions, whether there was a normal or a decreased capacity of the kynurenine pathway.
7. It is concluded that a single determination of urinary excretion of tryptophan metabolites after a loading dose of 2 g of t-tryptophan is sufficient to determine the capacity of the kynurenine pathway. 1. An outline of the kynurenine pathway of tryptophan metabolism. Roman numerals indicate enzymes functioning at indicated sites of the pathway: I, tryptophan pyrrolase; II, kynurenine hydroxylase; III, kynureninase; IV, kynurenine transaminase. B 6 indicates known sites of action of the coenzyme, pyridoxal phosphate. Metabolites in the box to the left are those that are known to accumulate when kynureninase activity is decreased. 3-Hydroxyanthranilic acid and metabolites in the box to the right are those expected to be formed in decreased amounts when kynureninase activity is decreased.
To demonstrate these changes in urinary excretion of tryptophan metabolites in human subjects, it is most often necessary to administer a loading dose of tryptophan. A wide range of doses have been used by different workers in this field. Since the administration of a loading dose of tryptophan, as pointed out by Chiancone (1965) , may be considered a 'test offunction', such a load should stress but preferably not exceed the capacity of the kynurenine pathway in normal subjects. One purpose of the present study was to investigate whether the tryptophan loading dose of 2 g of L-tryptophan usually used in our laboratory exceeds the capacity of the kynurenine pathway in a group of normal young male subjects and in a group of elderly male subjects with prostatic diseases.
In recent studies from our laboratory on the effect of hormones on urinary excretion of 239 tryptophan metabolites (Wolf, Price, Brown & Madsen, 197Oc; Wolf et al., 1970a) we have compared urinary excretion before and during treatment in the same subjects. Another purpose of the present study was to investigate whether urinary excretion of tryptophan metabolites after a loading dose of 2 g of L-tryptophan was constant in a subject when studied under unchanged conditions.
MATERIAL
Fifteen young male subjects free from any known diseases, fifty-five elderly male subjects with prostatic diseases, either benign hypertrophy or cancer of the prostate, and two patients with cancer of the bladder were included in these studies. This category of patients was selected . because it represents a rather homogeneous group of elderly subjects that could easily be studied. All subjects were ambulatory without any acute inflammatory processes, bladder infection or haematuria. They were not in acute distress or were not studied in the postoperative period. They did not suffer from any other diseases that are known to be accompanied by abnormal tryptophan metabolism. They received a regular hospital diet with a normal supply of protein, vitamins and minerals. Since vitamin B 6 plays an important role in the degradation of tryptophan along the kynurenine pathway, its main urinary excretion product,4-pyridoxic acid, was measured to ensure that dietary intake of vitamin B 6 was adequate. Dietary irregularities such as missing meals or excessive food intake were avoided. Additional dietary control appears to have little effect on the excretion of tryptophan metabolites in the urine in such studies (Price, Brown & Ellis, 1956) . During a pre-study period of 14 days drugs, antibiotics, irradiation, vitamins and other nutritional supplements were avoided, since they may interfere with the metabolism of tryptophan or with the analytical procedures used (price, Brown & Yess, 1965) . In these studies some of the subjects were treated with female sex hormones or hydrocortisone. The effect of these hormones on urinary excretion of tryptophan metabolites has been reported elsewhere (Wolf et al., 1970a, c) .
METHODS

Urine collection
Urine samples were collected each 24 h. As a quantitative check creatinine was determined on each urine sample. Patients with a residual urine volume of more than 30 ml were catheterized at the beginning and end of each collection period. The length of time the urine remains in the bladder has been found to have no influence on urinary excretion of tryptophan metabolites in human subjects (Wolf, Madsen & Price, 1968) . The urine samples were preserved by the addition of 20 ml of toluene and refrigerated at 0--40 on collection. If the samples were not analysed within a few days, they were kept frozen until the analytical procedures were carried out.
Tryptophan load and vitamin B 6 supplementation
The metabolic studies were usually carried out for two or four consecutive 24 h periods starting at 7 a.m, During the first 24 h period a basal urine sample was obtained. During the next 24 h period urine was collected after the administration of a 2 g loading dose of t-tryptophan. This was given with the breakfast, usually about 7.30 a.m. On the third day, 25 mg of pyridoxine-HCl was given four times: at 8 a.m., 12 noon, 4 p.m. and 8 p.m., and the urine was again collected. The administration of pyridoxine-HCl (4 x 25 mg) was repeated on the fourth day, together with a loading dose of 2 g of L-tryptophan also given with the breakfast.
Analytical methods used
The following urinary metabolites of tryptophan were determined: kynurenic acid, xanthurenic acid, indican, anthranilic acid glucuronide, o-aminohippuric acid, acetylkynurenine, kynurenine and 3-hydroxykynurenine. The main metabolite of vitamin B 6 in the urine, 4-pyridoxic acid, was also determined. The metabolites of tryptophan and vitamin B 6 were separated from each other and from interfering substances by the use of ion-exchange chromatography, after which the amount of the isolated metabolite was determined either by a colorimetric or fluorimetric assay. These analytical methods have previously been described in detail (Price et al., 1965; Wolf et al., 197Oc ). Table 1 shows the urinary excretion of tryptophan metabolites and 4-pyridoxic acid before and after a loading dose of 2 g of L-tryptophan (before and during supplementation with vitamin TABLE 1. Average urinary excretion of tryptophan metabolites and 4-pyridoxic acid before and after a loading dose of 2 g of L-tryptophan (before and during supplementation with 100 mg of pyridoxine-HCl daily) in fifteen normal young male subjects. Values are expressed as average nmol of metabolite excreted (± SD)/24 h. The scheme at the top of the B 6 ) in a group of young male subjects. After a loading dose of 2 g of t-tryptophan there is an increase in urinary excretion of anthranilic acid glucuronide, o-aminohippuric acid, kynurenic acid, acetylkynurenine, kynurenine, 3-hydroxykynurenine and xanthurenic acid, whereas urinary excretion of indican and 4-pyridoxic acid is unchanged. On the third day urinary excretion of these metabolites has returned to the same level as on day 1. On the fourth day there is a similar increase in urinary excretion of these metabolites as on day 2. Urinary excretion of 4-pyridoxic acid, as would be expected, is increased when supplemental vitamin B 6 is given. The normal limits for urinary excretion of these metabolites of tryptophan after a loading dose of 2 g of L-tryptophan in male subjects are defined as the average urinary excretion found in the group of young male subjects ±3 standard deviations. On this basis thirty-three of forty-eight subjectswith prostatic diseases studied before any hormone treatment were normal with regard to tryptophan metabolism. The mean basal and post-tryptophan excretion of urinary metabolites of tryptophan and 4-pyridoxic acid in these thirty-three subjects is given in Table 2 . Of these subjects eight were studied after supplementation with vitamin B 6 and these results, which agree with the results found in young male subjects, are also given in Fig.  2 . Thus, about three-quarters of a group of elderly subjects with prostatic disease respond to a loading dose of 2 g of L-tryptophan and supplementation with vitamin B 6 in the same way as young male subjects.
RESULTS
The mean basal urinary excretion of tryptophan metabolites and 4-pyridoxic acid in thirteen subjects showing abnormal urinary excretion of one or more tryptophan metabolites after a loading dose of 2 g of t-tryptophan, is shown in Table 3 . The mean basal urinary excretion of kynurenine (P<0'05) and 3-hydroxykynurenine (P < 0'02) is higher in these subjects than in the subjects showing normal urinary excretion of tryptophan metabolites after a loading dose of 2 g of L-tryptophan. Basal urinary excretion of the other tryptophan metabolites and 4-pyridoxic acid is not significantly different in the two groups. Table 3 also shows urinary excretion of tryptophan metabolites after a loading dose of 2 g of t-tryptophan in individual subjects with abnormally high urinary excretion of one or several tryptophan metabolites. In all cases kynurenine, 3-hydroxykynurenine or both are elevated. In about half of the subjects urinary excretion of xanthurenic acid is also increased, whereas urinary excretion of kynurenic acid and acetylkynurenine is only elevated in a few subjects. Of the subjects with abnormal tryptophan load tests six were given supplemental vitamin B 6 at some time during the period of study. Table 4 shows that it was possible in all six cases to normalize urinary excretion of tryptophan metabolites after a loading dose of 2 g of t-tryptophan with vitamin B 6 .
Urinary excretion of tryptophan metabolites before and after a loading dose of 2 g of L-tryptophan was studied twice in each of twenty subjects at various time-intervals ranging from I to 106 days. Excretion of individual tryptophan metabolites on these two occasions is shown in Fig. 2 . Some of the subjects were studied while receiving a female sex hormone or hydrocortisone, but each subject was on these two occasions in a comparable clinical state. TABLE 3. Average basal urinary excretion of tryptophan metabolites and 4-pyridoxic acid and excretion after a loading dose of 2 g of t-tryptophan in subjects with prostatic disease, who showed abnormal urinary excretion of one or more tryptophan metabolites. Values are expressed as JlIIlol of metabolite excreted/24 h. In the basal urine data the values are expressed as average jlmol of metabolite excreted (±SD)/24 h. The value in parentheses indicates the number of subjects in whom a basal urine was obtained. Abbreviations in parentheses indicate the patient's diagnosis: H.P., hypertrophy of the prostate; Ca.P., cancer of the prostate. Values in italics are those that were more than 3 SD above the mean for young male subjects. The scheme at the top of the table indicates the metabolic interrelationships of the urinary products of tryptophan. The abbreviations used are those of TABLE 4 . Urinary excretion of tryptophan metabolites and 4-pyridoxic acid after a loading dose of 2 g of L-tryptophan during supplementation with 100 mg of pyridoxine-HCI daily in six subjects with prostatic disease, who showed abnormal urinary excretion of tryptophan metabolites (see Table 3 ). Values are expressed as pmol of metabolite excreted/24 h. Abbreviations in parentheses indicate the patient's diagnosis: H.P., hypertrophy of the prostate; Ca.P., cancer of the prostate. The scheme at the top of the table indicates the metabolic interrelationships of the urinary products of tryptophan. The abbreviations used are those of The availability of the coenzyme, pyridoxal phosphate, for the kynureninase reaction seems to be the limiting factor for the capacity of the kynurenine pathway. Thus, the capacity of the kynurenine pathway is exceeded when there is a lack of pyridoxal phosphate as in vitamin B 6 deficiency. The capacity of the kynurenine pathway may also be exceeded (Altman & Greengard, 1966) when the flow of tryptophan along the kynurenine pathway is increased, as seen after induction of tryptophan pyrrolase by hydrocortisone. In the latter case there is a relative lack of pyridoxal phosphate to an increased demand. In both cases there is an imbalance between the formation of kynurenine and the further degradation of 3-hydroxykynurenine, which will result in accumulation of these two compounds and their metabolites, that are independent of kynureninase ( Fig. 1) . This imbalance can be demonstrated in vivo by determining urinary excretion of tryptophan metabolites after a loading dose of tryptophan. In both cases urinary excretion of these metabolites is increased compared with the excretion in normal subjects and if excess of vitamin B 6 is given together with the loading dose of tryptophan, urinary excretion of these metabolites is normalized.
One criticism of the use of a loading dose of tryptophan to study tryptophan metabolism has been that the dose itself may change tryptophan metabolism by induction of tryptophan pyrrolase (Knox, 1958) . However, if a loading dose of only 2 g of L-tryptophan is used, then there is no induction of tryptophan pyrrolase in human subjects (Altman & Greengard, 1966) . In addition, as demonstrated here, the capacity of the kynurenine in a group of normal young male subjects is not exceeded by a loading dose of 2 g of L-tryptophan, since the increase in urinary excretion of tryptophan metabolites after this dose is not lowered when excess of vitamin B 6 is given (Fig. 3) . Similar results where obtained in male subjects by Coon (1966) who studied urinary excretion of 3-hydroxykynurenine and xanthurenic acid after a loading dose of 2 g of L-tryptophan before and after supplementation with vitamin B 6 . The increase in urinary excretion of tryptophan metabolites after the loading dose of 2 g of L-tryptophan (Fig. 3) probably shows that more tryptophan is metabolized along the kynurenine pathway without qualitatively changing the metabolism of tryptophan along this pathway. Such a suggestion is in agreement with studies in human subjects with 14C-labelled tryptophan (Hankes, Brown, Lippincott & Schmaeler, 1967) .
Therefore, it seems reasonable to conclude that a loading dose of only 2 g of t-tryptophan is preferable when studying the capacity of the kynurenine pathway. Such a loading dose has for other reasons previously been recommended by Coursin (1964) . The loading dose of 2 g of t-tryptophan, however, seems to be close to the limit for the capacity of the kynurenine pathway. Thus, Crepaldi & Parpajola (1964) found a slight decrease in urinary excretion of tryptophan metabolites after vitamin B 6 supplementation when using this dosage. With a loading dose of 5 g of t-tryptophan which has often been used in studies in human subjects (Rose, 1966 (Rose, , 1967 Rose & McGinty, 1968) , the capacity of the kynurenine pathway has been found to be exceeded. Thus, Coon (1966) found that the increase in urinary excretion of 3-hydroxykynurenine and xanthurenic acid was significantly diminished after vitamin B 6 supplementation when a loading dose of 5 g of t-tryptophan was used. Similarly, Rose & McGinty (1968) found that vitamin B 6 supplementation resulted in decreased urinary excretion of kynurenine, 3-hydroxykynurenine and xanthurenic acid (combined) after a loading dose of 5 g of t-tryptophan from 297 and 380 Jlmol to 191 and 241 Jlmol in two subjects respectively. However, a loading dose of 2 g of L-tryptophan is not sufficient to detect constantly the sex difference in urinary excretion of metabolites of the kynurenine pathway. Such a difference was demonstrated by Michael, Drummond, Doeden, Anderson & Good (1964) , who found that female subjects excreted significantly more metabolites of the kynurenine pathway than male subjects after a loading dose of 100 mg of t-tryptophan/kg body weight. Similar results were obtained by Rose (1967) with a loading dose of 5 g of't-tryptophan, After a loading dose of only 2 g of L-tryptophan no difference in urinary excretion of metabolites of the kynurenine pathway between female and male subjects could be found in our laboratory (price et al., 1965) . Thus, if a difference in urinary excretion of metabolites of the kynurenine pathway produced by differences in the endogenous concentration of sex hormones is to be demonstrated a loading dose of 5 g of L-tryptophan seems preferable.
In the group of forty-eight elderly male subjects with prostatic disease we found that the capacity of the kynurenine pathway was normal in thirty-three subjects (Table 2 ). In the other fifteen subjects, however, the loading dose of 2 g of t-tryptophan produced increased urinary excretion of one or more tryptophan metabolites of the kynurenine pathway (Table 3) , indicating that in these subjects the capacity of the kynurenine pathway was exceeded. The capacity of the kynurenine pathway could be normalized by excess of vitamin B 6 (Table 4) . The difference in average basal urinary excretion of kynurenine and 3-hydroxykynurenine between the two groups may indicate that in the latter group dietary intake of tryptophan also exceeded the capacity of the kynurenine pathway.
From a clinical point of view the two groups of subjects did not differ from each other. Similar observations have been made in several other clinical states (Musajo & Benassi, 1964) . It has been suggested by Altman & Greengard (1966) that the abnormal tryptophan metabolism seen in these different states is due to stress-induced increase in tryptophan pyrrolase activity. It is in agreement with such a suggestion that a higher percentage of patients with cancer of the prostrate was in the abnormal group than of patients with benign prostatic hypertrophy. Lack of pyridoxal phosphate for the kynureninase reaction, which also could explain the decreased capacity of the kynurenine pathway seen in some of the subjects studied, is a less probable
